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Abstract
Background: The proper assembly of the transcriptional initiation machinery is a key regulatory
step in the execution of the correct program of mRNA synthesis. The use of alternative
transcription start sites (TSSs) provides a mechanism for cell and tissue specific gene regulation.
Our knowledge of transcriptional initiation sequences in the human genome is limited despite the
availability of the complete genome sequence. While genome wide experimental and bioinformatic
approaches are improving our knowledge of TSSs, they lack information concerning genes
expressed in a restricted manner or at very low levels, such as tissue specific genes.
Results: In this study we describe the mapping of TSSs of genes expressed in human retina. Genes
have been selected on the basis of their physiological or developmental role in this tissue. Our
work combines in silico analysis of ESTs and known algorithm predictions together with their
experimental validation via Cap-finder RACE. We report here the TSSs mapping of 54 retina
expressed genes: we retrieved new sequences for 41 genes, some of which contain un-annotated
exons. Results can be grouped into five categories, compared to the RefSeq; (i) TSS located in new
first exons, (ii) splicing variation of the second exon, (iii) extension of the annotated first exon, (iv)
shortening of the annotated first exon, (v) confirmation of previously annotated TSS.
Conclusion: In silico and experimental analysis of the transcripts proved to be essential for the
ultimate mapping of TSSs. Our results highlight the necessity of a tissue specific approach to
complete the existing gene annotation. The new TSSs and transcribed sequences are essential for
further exploration of the promoter and other cis-regulatory sequences at the 5'end of genes.
Background
The spatial and temporal regulation of gene transcription
is primarily determined by it's flanking promoter (cis-reg-
ulatory DNA elements) through interaction with trans-act-
ing regulatory proteins (transcription factors) [1,2]. The
start of transcription is accomplished by the formation of
a pre-initiation complex on the DNA, yet our knowledge
of transcriptional initiation sequences in the human
genome is still limited despite the availability of the com-
plete genome sequence [3,4]. Therefore one of the main
remaining challenges is to locate these gene sequences,
defined as the transcription start site (TSS), in order to
explore core promoter and cis-regulatory elements that
direct the start of every transcript. Genomic structure and
full length cDNA sequences aligned on the genome pro-
vide opportunities to locate TSSs. Conventional methods
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for determining exact TSSs, such as 5' RACE or primer
extension are laborious and are not selective for the com-
plete transcript. Consequently, many mRNA sequences
stored in public databases lack information about their
genuine 5' ends, mainly due to the difficulties in obtain-
ing full-length cDNA. Several bioinformatic and experi-
mental approaches have been developed to explore full-
length cDNAs and the human transcriptome [5]. Compu-
tational predictions may represent a powerful tool to
localize first exons and TSSs on an averaged genome-wide
scale [6,7], however they may fail at the level of individual
genes or in genes with complex regulatory patterns (e.g.
multiple or tissue-specific TSS).
Recently a number of experimental approaches to com-
pile TSSs on a genome-wide scale have been established
including the Database of human Transcriptional Start
Sites (DBTSS) [8], whole genome tilling array analysis [9],
and the exploration of mouse and human CAGE tag
libraries [10]. To enable future progress we need to com-
plete and revise these catalogues with an accurate annota-
tion of the 5' and 3'end, and include splice isoforms of the
transcripts. In addition to genome wide approaches, there
is a need for more specific studies, which cover tissue spe-
cific genes, expressed in a restricted manner. Identification
of potential transcription signals that are tissue specific
relies on the correct determination of transcriptional start
sites.
In this work we describe an experimental approach to
identify the TSSs of a selected group of genes, which are
predominantly expressed in retina. We focused our atten-
tion on the human retina, due to its unique and special-
ised function. This complex tissue, composed of multiple,
highly differentiated and specific cell types (e.g. rod and
cone photoreceptors, amacrine cells, Mueller glial cells),
expresses a large number of specific genes. Mutations in
many of these genes result in blinding disorders. The sub-
set of genes expressed in human retina has been partially
elucidated [11,12], with a number of studies defining
genes that are either highly expressed in retina or which
pose a crucial target of transcription factors in this tissue
[13-16]. We selected a pool of retina expressed genes and
employed Cap selective RACE to ensure amplification and
subsequent cloning of genuine TSSs. We describe herein
the results of this analysis, reporting the correct TSSs
within this group of retinal transcripts.
Results
Genes Selection and in silico assembly
76 annotated genes were selected for analysis. The selec-
tion was done based on the following criteria: (i) specific
or high levels of expression in retina, (ii) a role in retina
specific physiological processes or retinal development,
and (iii) involvement in retinal disease. A compilation of
all tested genes including gene symbol, definition, chro-
mosomal location and tissue/cell type of expression is
shown in Additional file 1.
cDNA and transcript sequences available in public data-
bases (RefSeq, NCBI and Ensemble gene predictions cov-
ered by at least one EST, Unigene ESTs database) were
downloaded and new assemblies generated using Seq-
Man.
We found that 5' transcript termini represented in public
datasets can be readily identified by clusters of cDNA ends
in the assemblies. Additionally, the information about
putative TSSs was assessed in The Eukaryotic Promoter
Database [17] and Database of Transcriptional Start Sites
(DBTSS) [8]. These data were compiled to create a prelim-
inary gene model which was used to design primers for
the subsequent Cap-finder RACE experiments.
Experimental examination of TSSs
Cap-finder RACE cDNA fragments were cloned and a var-
iable number of clones were sequenced for each gene,
depending on the number and the sizes of the colony PCR
products detected on the gel. We obtained products for 54
genes out of the 76 genes analysed. A summary of the
results obtained with Cap-finder RACE is shown in Tables
1. Genes for which the promoter and TSS were already
known (RHO and OPN1SW) served as internal positive
controls. For each gene we detected at least one splice var-
iant that agreed with one or more RefSeq annotated
exons.
Our strategy relies on the location of gene specific primers
within internal exons. We obtained those cDNA products
that covered at least one exon-exon junction and thus
ruled out the possibility of amplification of genomic con-
tamination. This strategy has enabled us to identify alter-
natively spliced 5' ends that arise from tissue specific gene
expression and regulation.
Table 1 lists the results of the Cap-finder RACE experi-
ments for 54 retinal expressed genes and the correspond-
ing RefSeq entry (database release 18). These results can
be grouped into five categories with reference to RefSeq;
(i) new TSSs within novel exons (8 genes), (ii) alternative
splice form of the second exon (2 genes: IMPG1, SAG),
(iii) extension of the annotated first exon (27 genes), (iv)
length shortening of the annotated first exon (4 genes),
(v) confirmation of previously annotated TSSs (13 genes).
Table 1 provides the exact nucleotide positions of 5' ter-
mini of the Cap-finder RACE cDNA clones referring to the
UCSC Human Genome Browser (March 2006 assembly).
In defining the interval where TSSs are located we report
the start, and when present, the internal frequent start and
end nucleotide position of each TSS. Sequences from thisBMC Genomics 2007, 8:42 http://www.biomedcentral.com/1471-2164/8/42
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Table 1: Results of the RACE experiment to determine the TSS of retina transcripts
Gene Symbol RACE results TSS location Chr. Shape CAGE
Start Int. peak End
C1orf32 Two new first exons Isoform a 165,208,791 1q24.1 SP +
Isoform b 165,269,346 --
Extension exon 0 of 
180 bp
Isoform a 98,329,050 98,329,083 2q11.2 BR +
CNGA3 Isoform b 98,329,288 SP -
Isoform c 98,329,371 SP +
DHRS3 New first exon Isoform a 12,578,722 1p36.1 SP -
Shorter exon 1 of 508 
bp
Isoform b 12,599,903 12,599,935 SP -
ELOVL5 New first Exon 53,320,946 6p21.1-p12.1 --
KIFC3 Two new first exons Isoform a 56,437,970 16q13-q21 SP -
Isoform b 56,370,953 SP -
RCV1 Extension exon 1 of 
203 bp
Isoform a 9,749,613 9,749,402 9,748,934 17p13.1 PB -
New first Exon Isoform b 9,745,910 --
Lack of exon 1. exon 2 
extended
Isoform c 9,745,244 9,745,221 MU -
RDH12 Two new exons 67,254,268 67,254,276 67,257,284 14q24.1 MU -
Isoform c 19,778,103 9p22-p13 SP -
SLC24A2 Two new first exons Isoform a 19,778,808 --
Isoform b 19,778,609 -+
Isoform d 19,776,949 19,777,002 PB +
Lack of exon 2 76,839,115 76,839,078 6q14.2-q15 SP -
IMPG1 Lack of exon 1. 
shortening exon2
76,808,496 SP -
Complete in the first 3 
Exons
76,839,060 --
SAG Lack of exon 2 233,998,462 233,998,525 2q37.1 BR -
AIPL1 61 bp 6,279,208 6,279,306 17p13.1 --
AOC2 10 bp 38,250,126 17q21 SP +
CLUL1 31 bp 606,669 606,693 606,698 18p11.32 PB -
CNGB3 43 bp 88,404,286 88,404,354 8q21-q22 --
EYA3 14 bp 28,287,732 28,287,684 1p36 BR +
FSCN2 66 bp 77,109,947 77,109,997 17q25 --
GNAT1 44 bp 50,204,027 50,204,047 3p21 --
GRK7 40 bp 142,979,632 142,979,726 3q21-q23 BR -
GUCA1B 19 bp 42,270,691 42,270,689-42,270,672 42,270,649 6p21.1 PB -BMC Genomics 2007, 8:42 http://www.biomedcentral.com/1471-2164/8/42
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GUCY2D 30 bp 7,846,687 17p13.1 --
HPCA 15 bp 33,124,670 33,124,680 2p25.1 MU +
IMPDH1 206 bp 127,837,736 7q31.3-q32 SP +
IMPG2 23 bp 102,522,132 102,522,102 3q12.2-q12.3 BR -
LRRC21 Extension exon 1 of 121 bp 85,991,318 85,991,280 85,991,194 10q23 PB -
MPP4 30 bp 202,271,692 202,271,616 202,271,601 2q33.2 PB -
OPN4 67 bp 88,404,287 10q22 SP -
PDC 17 bp 184,696,879 184,696,869 1q25.2 MU -
PDE6H 7 bp 15,017,238 15,017,243 12p13 SP -
PRPF31 117 bp 59,310,532 59,310,609 19q13.42 MU -
RdCVF 37 bp 17,432,763 17,432,753-17,432,735 17,432,716 19p13.11 MU -
RDH5 39 bp 54,400,449 12q13-q14 SP -
RDH8 63 bp 9,984,862 9,984,925 9,984,991 19p13.2-p13.3 MU -
RDS 61 bp 42,798,348 42,798,296 6p21.2-p12.3 BR -
RLBP1 83 bp 87,566,008 87,565888 15q26 --
ROM1 215 bp 62,136,883 62,137,111 11q13 BR -
RPGR 7 bp 38,071,739 38,071,704 Xp11.4 BR -
TULP1 70 bp 35,588,693 35,588,651 6p21.3 PB +
CRB2 52 bp 125,158,322 125,158,324 9q33.2 --
CRX Shortening exon 1 of 60 bp 53,016,971 53,017,001 53,017,005 19q13.3 SP -
RP1 53 bp 55,691,206 55,691,233 8q11-q13 BR +
WDR17 77 bp 177,224,132 177,224,169-177,224,185 177,224,202 4q34 MU +
ABCA4 94,359,290 94,359,245 1p22.1-p21 BR -
C14ORF2 103,457,619 14q32.33 -+
C1QL2 119,632,934 2q14.2 --
C7orf9 25,427,912 7p21-p15 --
CHM 85,189,194 85,189,222 Xq21.2 BR +
ELOVL4 80,714,034 6q14 -+
OPN1SW Previous 5' end confirmed 128,203,084 7q31.3-q32 SP -
RAX 55,091,570 18q21.32 SP -
RBP3 48,010,989 48,011,000 10q11.2 --
RDH11 67,232,201 67,232,186 14q24.1 SP -
RHO 130,730,174 3q21 SP -
RPL14 40,473,831 3p22 SP +
RS1 18,600,144 Xp22.2-p22.1 SP -
The Table provides Gene Symbols of the processed genes, RACE results referring to the RefSeq entry (database release 18), nucleotide position of 
the TSS (start, internal frequent start and end) referring to the UCSC Human Genome Browser (March 2006 assembly), Chromosomal location 
(Chr.), shape of the TSS (Shape) according to the classification of Carninci et al., 2006: single peak [SP], broad [BR], bimodal/multimodal [MU], 
broad with dominant peak shape [PB], comparison with Cage TSS database (+ for correspondence, – no correspondence). The genes are listed 
according to the type of results that was obtained according to the description in the text: (i) new TSSs within novel exons (8 genes), (ii) alternative 
splice form of the second exon (2 genes:, (iii) extension of the annotated first exon (27 genes), (iv) length shortening of the annotated first exon (4 
genes), (v) confirmation of previously annotated TSSs (13 genes).
Table 1: Results of the RACE experiment to determine the TSS of retina transcripts (Continued)BMC Genomics 2007, 8:42 http://www.biomedcentral.com/1471-2164/8/42
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study have been submitted to GenBank under the acces-
sion numbers: DQ067456–DQ067464, DQ426859–
DQ426897, DQ980599–DQ980621.
Retinal expressed genes with new 5' exons
For 8 genes (C1orf32, CNGA3, DHRS3, ELOVL5, KIFC3,
RCV1, RDH12, SLC24A2) we have identified a new exon
composition at the 5' end of the transcript and in some
cases new untranslated 5' exons that locate the TSS several
kilobases upstream or downstream from the annotated
one.
- C1orf32. This transcribed locus in chromosome 1 was
selected for its retinal expression. For this gene, whose
function is still not characterised, we retrieved two new
isoforms lacking the first annotated exon found in RefSeq.
These isoforms contain TSSs in two new exons. One form
displays a new first exon located 3 kb downstream from
the previous TSS. The other form presents a first exon
located 58,4 kb upstream of the former TSS, generating a
new first intron spanning a locus transcribed in the oppo-
site strand, the gene MAEL. (Figure 1A)
- CNGA3 (cyclic nucleotide gated channel alpha 3) codes
for the α-subunits of the cone photoreceptor cGMP-gated
channel, a crucial component of the cone phototransduc-
tion cascade in colour vision. Mutation in this gene causes
achromatopsia. The RACE experiment confirmed the pres-
ence of 4 isoforms, all containing a splicing of untrans-
lated exon 0 localised 23,4 kb upstream of exon1 [18]
(Figure 1B).
- RDH12 (Retinol dehydrogenase 12) is an enzyme with
dual-specificity retinol dehydrogenases that metabolise
both all-trans- and cis-retinols, reported to be expressed in
photoreceptors [19]. Mutations within RDH12 cause both
recessive early onset Retinitis pigmentosa and Leber's con-
genital amaurosis [20,21]. In human retinal mRNA we
retrieved two forms of the transcripts containing a new
first exon located upstream of the RefSeq TSS and a differ-
entially spliced second exon. The in silico assembly and
experimental pipeline allowed us report three putative
TSSs for this gene; the first is defined by the RefSeq anno-
tation, the second was deduced from the most upstream
transcript represented by ESTs from pooled colon and the
third is a new TSS displayed by retinal transcripts (Figure
1C).
- DHRS3 (dehydrogenase/reductase, SDR family, member
3) codes for an enzyme catalysing the reduction of all-
trans-retinal to all-trans-retinol in the presence of NADPH
[19,22]. The gene was included in our study for its high
expression in retina. Cap-finder RACE confirmed the pre-
vious first exon and TSS. We also detected an alternative
TSS in a new first exon downstream from the annotated
one which was predicted with FirstEF [6]. (Additional file
2: Figure 5).
- ELOVL5 (elongation of long chain fatty acids, including
docosahexanoic acid (DHA), family member 5). This gene
was recently annotated as a retinal expressed gene [23]
and a target of mutation studies in retinitis pigmentosa
[24]. We detected a new form of the transcript with a new
first exon that was not previously annotated or described
for retina. (Additional file 3: Figure 6)
- KIFC3 (Kinesin family member C3) codes for a retina
specific microtubule-associated force-producing protein
that may play a role in intracellular transport [25]. We
have characterised two new isoforms of KIFC3  retinal
transcripts which lack the first 3 exons annotated in Ref-
Seq. Both transcripts include a new first exon that localizes
these new TSSs 44 kb upstream and 27 kb downstream
respectively from the TSS referenced in the RefSeq data-
base. The more upstream start site locates the gene in
proximity to another retina specific gene (CNGB1). (Addi-
tional file 4: Figure 7)
- RCV1 (recoverin) inhibits rhodopsin kinase activity in
retinal photoreceptors by reducing the binding of arrestin
to rhodopsin. Deregulation of recoverin expression in cer-
tain types of cancer demonstrates a pathological role in
cancer-associated retinopathy [26]. Although a previous
study of the promoter was performed [27], no clear evi-
dence of the TSS have been described. For this gene we
detected three alternative transcripts; the first with the
same 5' end as the previously annotated TSS (first exon
length may vary from 203 bp longer to 444 bp shorter),
the second with a more frequent isoform lacking the first
exon and starting 80 bp upstream from the second exon
of the RefSeq and the third form has a new first exon
located downstream from the annotated one. (Additional
file 5: Figure 8).
- SLC24A2 (solute carrier family 24, sodium/potassium/
calcium exchanger, member 2) codes for a potassium-
dependent sodium-calcium exchanger in cone photo-
receptor [28]. Although variant alleles of the cone
SLC24A2  gene have been identified, none of them are
definitively associated with a specific retinal disease [29].
The new model we present for SLC24A2 predicts three
putative TSSs located in two new additional exons that are
alternatively spliced (Additional file 6: Figure 9).
We also investigated whether the new exons that extend
the 5' end of the transcript may introduce new potentially
protein coding sequences. We didn't observe in any case
an extension of the open reading frame beyond the anno-
tated start codon. However short alternate open reading
frames of at least 40 codons were observed for C1orf32BMC Genomics 2007, 8:42 http://www.biomedcentral.com/1471-2164/8/42
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Schematic gene structure of 3 analysed genes Figure 1
Schematic gene structure of 3 analysed genes. Schema of the RefSeq, ESTs, exonic structure of new isoforms identified 
with the Cap-finder RACE of human retina mRNA and the genomic structure containing the TSSs indicated by arrows. Red 
Arrows indicate new retina TSSs. A) C1orf32. Transcripts in human retina: isoform a contains a new first exon located 2.7 kb 
downstream from previous TSS, isoform b presents a first exon 58,5 kb upstream the previous TSS. This second transcript 
defines an intron containing another transcribed locus in the opposite strand, the gene MAEL. B) CNGA3: Cap-finder RACE of 
human retina mRNA confirmed the presence of an untranslated exon localised 23,4 kb upstream of exon1. One isoform con-
tains alternatively spliced variant of exon 0 (asterisk). C) RDH12: the schematic representation of EST from human retina 
shows two forms of the transcripts starting in a new retina TSS. These two isoforms contain two alternatively spliced variants 
of the second exon (asterisk).
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(nucleotide position 18–290 from the TSS in isoform a,
and position 164–400 in isoform b), CNGA3 (position
166–315), DHRS3 (position 166–315), KIFC3 (position
4–195), and SLC24A2 (position 55–183 isoform a, 44–
289 isoform b). Yet the translated sequences of these short
ORFs do not have homology with any protein in public
databases.
Detection of novel splicing variants and shorter transcripts
Our experimental procedure described alternatively
spliced isoforms for two genes IMPG1, SAG, which lack
exon 2 of the RefSeq. These forms have not been anno-
tated in the RefSeq database. We confirmed these alterna-
tively spliced isoforms by regular RT-PCR (Data not
shown). The second exon of the gene SAG contains the
TSS and the presence of this alternative form, lacking the
regular start site, may play a role in the regulation and fur-
ther processing of the transcript. For 4 genes (CRB2, CRX,
RP1, WDR17), we detected shorter transcripts that lack the
annotated start codon. Since these experiments were done
with the same adapter ligated first-strand cDNA we
assume that these short transcripts are derived from true
alternative TSSs. These transcripts may be preferentially
amplified in the RT-PCR and may be translated from an
internal initiation codon. We report in Table 1 the
detailed results for these genes.
Confirmation of results with primer extension
To provide an experimental validation of our results we
undertook primer extension experiments. We performed
reverse transcription of mRNA with a sequence-specific
FAM-labelled primer for two genes (CNGA3, RDH12).
The length of the FAM-labelled cDNA primer extension
product can be analysed on ABI-DNA Genetic Analyser
using GeneScan software. As a result of the analyses we
detected a fragment of 350 bp for CNGA3 (Fig 2A) and a
fragment of 215 bp for RDH12 (Figure 2B). The size of
these fragments confirms the presence of the transcripts
that we detected with RACE.
Comparison with existing annotations and databases
To assess the quality of current annotations of the 5' end
of genes expressed in human retina, the sequences
obtained by 5' RACE were compared with the correspond-
ing gene annotation/prediction. Overall, RACE experi-
ments detected 15 exons that were neither annotated nor
predicted for retina transcripts; 8 exons did not have any
matching experimental evidence in GenBank, while the
other 7 showed different boundaries or alternative splice
sites. Of these 15 un-annotated exons, 12 are first exons
and can be considered the new first exon for the retinal
transcripts. Of the 54 genes successfully amplified, 41
(76%) delivered 5' RACE sequences different from the
annotation. Results of a parallel project, DBTSS [8], sup-
ported our results concerning 3 of these genes (CNGA3,
ELOVL5 and SLC24A2) although the source of mRNA was
not human retina. We extended the annotated first exon
of 27 RefSeq genes by an average of 60 transcribed bases.
We compared our results with genome wide mapping of
TSSs using CAGE tags [10]. We found perfect correspond-
ence for 13 transcript isoforms; for another 6 transcripts
the start site retrieved in the CAGE database is located less
than 400 bp away. For 35 transcript isoforms the TSS is
located in a different position (See Table 1). This discrep-
ancy in the results may be due to the fact that the CAGE
database doesn't include retina amongst the panel of ana-
lysed tissues and therefore lack specific and rare transcript
isoforms present in that tissue.
Shape of TSSs and conservation
After analyzing the distribution of RACE clones we could
define the shape of TSSs according to the classification
previously reported [10]. The different clones were clus-
tered and depending on the start base position of each
clone within a cluster we divided the start sites into four
shapes. In the single dominant peak class (SP) the major-
ity of clones are concentrated to no more than four con-
secutive start positions with a single dominant TSS. The
clusters spanning a broader region are grouped in a gen-
eral broad distribution (BR), a broad distribution with a
dominant peak (PB) and a bi- or multimodal distribution
(MU): 22 genes showed a single dominant peak, 11 a
broad distribution, 8 a bi-multi peak distribution and 6 a
broad distribution with a dominant peak. For some tran-
scripts we could not make a classification because the
number of clones was less than 5. We report the results of
this analysis Table 1 (TSS shape). Figure 3 shows a graph-
ical view of TSSs identified for AOC2, ABCA4, RDH12,
and LRRC21 as an example of the different distributions
observed. The classification of the shape of TSSs defined
by distribution of 5' end RACE clones within a cluster is
useful for the further characterization of expression regu-
lation. The distribution of the clones defines different ele-
ments of the core promoter and gives insights on the start
of transcription. Even if broad promoters are the major
class in mammals [10], 36 of the analysed transcripts
present a dominant peak highlighting the possibility that
those transcripts are tightly regulated.
Although TSSs of orthologous genes do not necessary
reside on equivalent locations because of evolution of
mammalian TSSs [30], we analysed sequence conserva-
tion of the first new exons among a set of mammals
(mouse, dog, cow): the range of conservation varies
between 42 and 89 %. We report the pairwise alignment
percentage of identity in Additional file 7.
Sequences residing upstream and downstream from the
boundaries of new defined exons are regions displaying
high regulatory potential calculated by a computationalBMC Genomics 2007, 8:42 http://www.biomedcentral.com/1471-2164/8/42
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Primer extension results from WERI-RB1 retina cell lines mRNA Figure 2
Primer extension results from WERI-RB1 retina cell lines mRNA. Primer extension products obtained with the gene 
specific primer for CNGA3 (A) and for RDH12 (B). The blue peaks in each panel correspond to the primer extension product 
(FAM-labelled cDNA). The elongation products size 350 bp and 215 bp were respectively expected from the data of RACE 
cDNA sequences (Blue arrow). Red peaks are the GeneScanR-500 ROX internal lane standards. In the y-axis is indicated the 
intensity of fluorescence, in the x-axis the number of nucleotides.
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algorithm [31] integrated in the UCSC genome browser.
The regulatory potential (RP) scores computed for the 500
bp sequence upstream the TSS shows that in 9 new first
exons out of 11 the RP value exceeds an arbitrary thresh-
old of 0.2 (data not shown). Considering 500 bp down-
stream the splice site of the first exon the RP value is > 0,2
at least for 7 first exons out of 11. This observation con-
firms the importance of the new described exons to locate
new regulatory elements that are important for transcrip-
tion in retina.
A high level conservation was observed for splice donor
sites of the new first exon. 5 genes show an average con-
servation of at least 75% in the region -3/+5 spanning the
splice donor site. For example, we report an inter-species
alignment of the 3' end of exon 0 (CNGA3). The sequence
conservation at the level of the splice donor site highlights
the possibility of a particular role for this splicing (Figure
4).
Discussion
Now that the information pertaining to the genomes of
human and other animals is available, the next challenge
for genetic studies is to map the TSSs and regulatory
sequences of the genes. Here, we carried out a study to
determine the genuine TSSs of a pool of retinal expressed
genes. The results give correct information about the com-
plete 5' end of transcripts and this data will be useful to
locate the respective core and proximal promoter ele-
ments. We chose Cap-finder RACE to map the TSS of reti-
nal expressed genes because this technique is selective for
the complete transcript [8,32]. For 41 out of 54 success-
fully amplified genes, the Cap-finder RACE experiments
detected transcripts which are different from the current
TSSs present different shapes Figure 3
TSSs present different shapes. Histograms indicate the number of RACE clones mapping at each nucleotide position. 
Examples show the different pattern that we observed during the analysis of the Cap-finder RACE. A) Clones distribution for 
AOC2 (single peak class: SP). B) Clones distribution for ABCA4 (broad: BR). C) Clones distribution for RDH12 (multimodal: 
MU). D) Clones distribution for LRRC21 (broad with dominant peak shape: PB).
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gene annotation In most cases the RefSeq was incomplete.
Transcripts were missing part of the first exon or even
complete exons at the 5' end. This experimental determi-
nation of TSSs shows that the current gene annotation was
in most cases obtained from data sources that are not
strictly selective for the complete transcribed form, and
need to be updated. This procedure led us to discover sev-
eral transcript isoforms that were un-annotated and to
locate retina specific TSSs. Proteins encoded by these
genes are essential for retina function and stability. A
mutation in the cis-regulatory elements may influence the
level of transcription and have a strong effect due to sen-
sitivity of photoreceptors for high level transcription of
genes involved in phototransduction. The new described
cis-regulatory regions and untranslated exons are possible
targets for mutation studies in retinal disorders. Therefore
new isoforms give a more complete picture of alternative
start sites use in retina genes. The 5' untranslated region
may contain important transcriptional and post transcrip-
tional regulatory sites [33-35] and therefore only the com-
plete 5' UTR provides the opportunity to study the
potential regulatory role of these non-coding sequences.
New reported TSSs contribute to the identification of reg-
ulatory elements active in tissue specific gene regulation
[36,37]. Moreover, bioinformatics tools that identify
common regulatory elements rely on the correct determi-
nation of TSSs within a particular tissue [38], therefore
these computational approaches will only be effective
after experimental validation of the 5' end of transcripts.
Conclusion
We herein report the TSSs for 54 retina expressed genes.
Our results define new and more precise locations of TSSs
for 76% of the analysed genes; moreover in 15% of the
genes we found new exons in the 5' end of the transcripts.
Thus, this analysis of TSSs in human retina was essential
to define the complex pattern of transcripts present in this
tissue.
Our results highlight the importance of applying a tissue
specific approach with a systematic program of Cap-finder
RACE using the known gene structures as a starting point
and/or gene predictions to complete the existing gene
annotation. The new TSSs and transcribed sequences pro-
vide crucial information for further exploration of the
promoter and other cis-regulatory sequences at the 5'end
of the gene, and in particular for the study those elements
that are functionally active in human retina.
Methods
In silico analysis
We used available public database information (RefSeq,
NCBI and Ensemble predictions covered by at least one
EST, Unigene EST database) to perform in silico assembly
and analysis of 5'transcript termini. The procedure
involves downloading the sequences from public data-
bases, clustering them to obtain a consensus and design-
ing a gene model with the most complete 5' transcript
termini. Sequences were downloaded and assembled
using the SeqMan program (DNAstar). In our analysis we
consider retina ESTs as well as non-retinal ESTs to obtain
the most complete information about the different alter-
native start sites already mapped. Additionally, the infor-
mation about putative TSS was assessed using Promoser
[39], Eukaryotic Promoter Database Current Release 87
[40], and Database of Transcriptional Start Sites DBTSS
[41]. First exon boundaries were determined by aligning
the predicted sequence to the genome using BLAT [42].
The gene model was then deduced considering the cluster-
ing of all the collected sequences giving the priority to the
most accurate database in the 5' termini (EPD and
DBTSS), but considering also gene prediction (GENS-
Inter-species alignment of exon-intron boundaries of the exon 0 of CNGA3 Figure 4
Inter-species alignment of exon-intron boundaries of the exon 0 of CNGA3. Conserved nucleotides are labelled 
with colours and with the star in the bottom those conserved in all the analysed species (human, mouse, rat, rabbit, dog cow, 
elephant and tenrec). Arrow highlights the splice donor site.
 
 
 
 
Human                            AGGAGGCGCTCCG-CAGACCCTGGCGCGCCGCGGAGAAGCTCAAACTTTGGCAGGGTAAGGATTTTTACTTGAG   
Mouse                            AGGAGTCGCTCTCCCAGATCCAGGCGCACC---AAGAAGCCCAAACTTTGACAGGGTAAGGA-CTCAATT-GAG   
Rat                                TGGAGTCGCTCTTCCAGATCCAGGTGCACC---GAGAAGCCCAAACTTTGACGGGGTAAGGA-CTCAATT-GAG   
Rabbit                          AGGAGCTGCTCGGCCGGACCGGGGCGCGCCGCGGAGAAGCTCAAAGTTTGGC-GGGTAAGGA-CCTGACTGGAG   
Dog                                AGGAGACGATTTGCCAGATAGAGGCGCGCCGCGGAG-AACTCCAACTTTGGC-GGGTAAGG--ATTGCCTAGGG   
Cow                                AGGAGACGCTCCGCCAGGCACAGGCGCGCTGCGGAG-AGCTCAAACTTTGGTGGGGTAAGGA-ATTTACTTGAG   
Elephan                        AGGAGACGCTCGGACAGAGGGAGGCACGGATCGCAGAAGCTCAAACTTTGGCAGGGTAAGGA-TTTTACCAGAG   
Tenrec                          AGGAGACGCTCGGACTGACCGAGGCG-AGCGCGCAGAAGCTCAAACTTTGGCGGGGTAAGGA-CTCAACCTGAG   
                                        ****    *  *        *  *          **                    **  *  *  *  **  ****      ********                    *  *   
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CAN, implemented in the UCSC Genome Browser) and
gene annotation that are confirm by at least one EST [43].
To evaluate first exons conservation we used BioEdit pair-
wise and multiple alignments [44]
Primer design
Gene specific reverse primers were selected within exons
other than the first exon to obtain spliced products. Two
primers were chosen for each gene, in order to perform a
nested PCR, which allows to enhance specificity, and to
obtain a sufficient amplification product for rare tran-
scripts. Primers were designed using the Primer3 software
[45], and checked for uniqueness by querying against the
human genome.
RACE protocol
We applied the RNA-ligase-mediated RACE (RLM-RACE)
system from Ambion. RNA sample from adult human ret-
ina was treated with DNAse I. After DNase treatment and
inactivation, 10 μg of total RNA was dephosphorylated for
60 min at 37°C with 10 U Calf Intestinal Phosphatase to
remove the 5'-phosphate from all RNA species except
those that have a cap structure (present on all Pol II tran-
scripts). RNA was then phenol/chloroform extracted, pre-
cipitated and re-suspended in water. Dephosphorylated
RNA was then digested for 60 min at 37°C in a 10-μL reac-
tion with 10 U tobacco acid pyrophosphatase. Subse-
quently the RNA was incubated for 60 min at 37°C with
1 U T4 RNA ligase and 0.3 μg of an RNA adapter (5' RACE
Adapter 5'-GCU-GAU-GGC-GAU-GAA-UGA-ACA-CUG-
CGU-UUG-CUG-GCU-UUG-AUG-AAA-3'). After liga-
tion, 180 ng of RNA was incubated for 2 min at 75°C in
the presence of 5 μM random decamers in RT buffer. Sin-
gle-stranded cDNA was generated by the addition of 100
U M-MLV RT and incubation at 42°C for 60 min.
Amplification of 5' RACE cDNA was carried out using
nested gene-specific primers and adapter specific primers
and with 1 μl of the first-strand cDNA reaction. PCR reac-
tions were done in 50 μl volume including 5 μl 10× PCR
Buffer supplied in the RLM kit, 4 μl dNTP Mix 10 mM, 2
μl 5' RACE gene-specific outer primer (10 μM), 2 μl 5'
RACE Outer or Inner Primer (10 μM), and 1 U thermosta-
ble DNA polymerase. Cycling conditions were: 5 min ini-
tial denaturation at 94°C PCR followed by 35 cycles of
95°C for 30 s, 60-55°C (empirically determined) for 30 s
(annealing), 72°C for 30 s (extension) and a final exten-
sion at 72°C for 7 mins. Amplified products were ana-
lysed on a 3% agarose gel and visualised by ethidium
bromide staining.
Cloning and sequencing of RACE products
5' RACE products were cloned into pCR-2.1 vector (Invit-
rogen). 2 μL of PCR reaction were incubated with 0.1 ng
of vector at 16°C over-night. Aliquots of the ligation were
used to transform library efficiency chemically competent
E. coli DH5α (Invitrogen). 8 to 48 clones of each transfor-
mation were subjected to colony PCR and the inserts
sequenced with standard M13 forward and reverse prim-
ers applying Big Dye Terminator v3.0 chemistry (Applied
Biosystems). Sequencing products were separated and
analysed on an ABI 3100 DNA sequencer.
Sequence analysis
Gene sequences and cDNA sequences, obtained using the
RACE, were aligned to the human genome using BLAT.
cDNA sequence was considered informative only if the
following criteria were met: (I) the spliced sequence
mapped to the same region of the genome as the gene
sequence; (II) the product could be mapped uniquely to
the genome with >95% identity and (III) presence of the
gene specific primer sequence and the 5' RACE Adapter
primer sequence.
Primer extension
A fluorescein phosphoramidites (FAM)-labelled reverse
primer was added to 10 μg of DNAseI-treated total RNA to
a final concentration of 5 nM. Samples were heated at
70°C for 5 min followed by 20 min incubation at 58°C
and then allowed to cool for 15 min to room temperature.
First strand cDNA synthesis was performed using Avian
Myeloblastoma Virus (AMV) reverse transcriptase and 5×
AMV-RT buffer (Promega) according to the manufac-
turer's instructions in a final volume of 60 μl. The primer
extension reaction was done in two repeated reaction
cycles. After an initial reverse transcription step (60 min at
42°C in a total volume of 50 μl), enzyme was replenished
and the samples underwent a second extension reaction
(60 min at 42°C, adjusting the buffer to a total volume of
60 μl). Finally 3 μl of 5 M NaOH was added to each cDNA
sample, the reaction incubated at 37°C for 15 min and
then neutralised with 16 μl of 2 M HEPES free acid. Exten-
sion products were purified using the columns AutoSeq
G-50 (Amersham Pharmacia Biotech). Samples were sep-
arated on 50-cm capillary columns in the POP4 acryl
amide polymer (Applied Biosystems) on an ABI PRISM
3100 Genetic Analyser (Applied-Biosystems) Sequencer
with GENESCAN 500-ROX added as size standard
(Applied-Biosystems). The sequences of the gene specific
reverse primers were: RDH12  5' tgagcagcagcctgactctgag-
caga gcccaga 3', CNGA3 5'atcttctcggtttgtcacatttagc 3', with
5' ends modified with the fluorescent molecule 6-FAM.
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